

Lebanon

Population 2016

6 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.061 (0.037–0.089)	1 (0.62–1.5)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.02 (0.01–0.02)
Incidence (includes HIV+TB)	0.74 (0.64–0.86)	12 (11–14)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.1 (0.09–0.12)
Incidence (MDR/RR-TB)**	0.029 (<0.01–0.05)	0.48 (0.14–0.83)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.039 (0.033–0.045)	0.27 (0.23–0.31)	0.31 (0.26–0.35)
Males	0.039 (0.033–0.045)	0.4 (0.34–0.45)	0.43 (0.37–0.5)
Total	0.078 (0.067–0.09)	0.66 (0.56–0.76)	0.74 (0.64–0.86)

TB case notifications, 2016

Total cases notified	657
Total new and relapse	646
- % tested with rapid diagnostics at time of diagnosis	22%
- % with known HIV status	74%
- % pulmonary	60%
- % bacteriologically confirmed among pulmonary	78%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.08 (0.05–0.12)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	4	<1%
- on antiretroviral therapy	3	75%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			18 (5–30)
Estimated % of TB cases with MDR/RR-TB	2.6% (0–5.4)	43% (9.9–82)	
% notified tested for rifampicin resistance	59%	67%	392
MDR/RR-TB cases tested for resistance to second-line drugs			2
Laboratory-confirmed cases		MDR/RR-TB: 10, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 10, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	83%	640
Previously treated cases, excluding relapse, registered in 2015	90%	10
HIV-positive TB cases registered in 2015	60%	5
MDR/RR-TB cases started on second-line treatment in 2014	67%	6
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	2%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	76% (56–100)

TB financing, 2017

National TB budget (US\$ millions)	2.8
Funding source: 36% domestic, 26% international, 38% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

